ESR1 and breast carcinoma: Based on their preferential activity against Y537S mutant breast cancer cells, we hypothesize that BET inhibitors may prevent or delay development of Y537S-mediated endocrine therapy resistance and disease recurrence when used in the adjuvant setting for treatment of patients with localized ER+ breast cancer.